Cover Image

Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters

Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell v...

Full description

Saved in:
Bibliographic Details
Main Authors: Misaki Ishibane (Author), Hirofumi Hashimoto (Author), Meika Kaneko (Author), Shota Saito (Author), Sangjon Pae (Author), Shinpei Saito (Author), Yoshie Reien (Author), Yuri Hirayama (Author), Nobuyo Higashi-Kuwata (Author), Hiroaki Mitsuya (Author), Naohiko Anzai (Author)
Format: Book
Published: Elsevier, 2022-12-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell viability and uptake assays, we examined the effects of E-CFCP on the function of renal organic anion transporters (OATs). No cytotoxicity was shown related to the E-CFCP in the renal OATs in either assay. Thus, this study suggested that E-CFCP may be a novel, excellent candidate drug for the treatment of drug-resistant HBV.
Item Description:1347-8613
10.1016/j.jphs.2022.09.002

Similar Items